How is the CARES kappa subgroup data changing your approach to newly diagnosed kappa AL amyloidosis?

The CARES trial was a negative phase 3 trial comparing standard-of-care therapy with or without anselamimab (an anti-amyloid monoclonal antibody) for newly diagnosed amyloidosis.

While the overall results were negative, there was a subgroup analysis that was prespecified that showed a significant sur...

Anselamimab (originally CAEL-101 & 11-1F4) is a chimeric immunoglobulin IgG1 kappa monoclonal antibody (mAb) directed against the human kappa light chain fibril and has shown preclinical reactivity against both isotypes, even though these preclinical studies seem like nonsense. It targets only the k...

These results are the first to demonstrate the potential impact of an anti-fibril therapy and are clearly an exciting advance for the field. However, clinical use of this approach is dependent on regulatory approval and further clarification of the results regarding its applicability outside of the ...

Agree 100% with @Ben Derman and @Craig C. Hofmeister! The only word of caution I'd add to their excellent answers is that this story (a prespecified subgroup analysis showing a clear benefit in a biologically plausible way with an anti-amyloid fibril) is not new.

With a related anti-amyloid fibril ca...